Published: August 3, 2026
Estimated reading time: 5 minutes
If you’ve heard that the rules around hormone therapy for menopause have changed — you heard right. New guidelines and updated Food and Drug Administration (FDA) communications are reshaping how doctors think about menopause hormone therapy, and the shift is good news for millions of women who’ve been experiencing hot flashes, sleep disruption and mood changes without much relief.
You may know it as hormone replacement therapy, or HRT. Clinicians are moving toward the term “menopause hormone therapy,” or MHT, to better reflect how and why it’s used — to restore hormones the body slows and eventually stops producing at menopause, not simply to “replace” something lost.
Menopause itself is defined as starting 12 months after a woman’s final menstrual period. The transition leading up to that point — perimenopause — can bring irregular cycles, hot flashes, sleep issues, mood swings and brain fog, sometimes years before periods actually stop.
“Perimenopause is the transition between normal regular periods and no periods,” said Anna K. Feitelson, M.D., OB/GYN with Norton Women’s Care. “We don’t look at labs to treat perimenopause; we look at the symptoms and manage those based on the patient’s individual experience.”
For roughly two decades, MHT use was shaped largely by a study: the Women’s Health Initiative (WHI), published in the early 2000s. That study raised alarms about heart disease, blood clots and breast cancer — and hormone prescribing dropped dramatically almost overnight.
The WHI was designed to study cardiovascular risk, not menopause symptoms. It enrolled women with an average age of 63 — many of whom were years past menopause and had never taken hormones. That’s a very different population than a 50-year-old with hot flashes and night sweats.
“The data that we had at the beginning of this century is not the data that we have now,” Dr. Feitelson said. “So the fear that we had at the beginning of this century, we don’t have now.”
Since then, newer studies — including a large Danish osteoporosis study — found that women who started estradiol (estrogen hormone) therapy around age 50 had a 50% reduction death from all causes and no increased risk of breast cancer. That research is helping offset the earlier, more alarming picture.
The FDA has updated its safety communications on MHT, including removing the black box warning that had long made patients and providers wary.
One of the most significant updates in the new HRT guidelines is the emphasis on how hormones are delivered. Transdermal estrogen — patches or gels applied to the skin — bypasses the liver, which meaningfully reduces the risk of blood clots compared with oral formulations, according to Dr. Feitelson.
Estradiol, the form of estrogen used in transdermal products, also behaves differently in the body than the estrogens used in older formulations. It appears to have a more favorable effect on blood vessels, with less impact on blood pressure and cardiovascular risk.
Women who still have a uterus need progesterone alongside estrogen to protect against uterine (endometrial) cancer. The newer option — micronized progesterone — has an added benefit: It acts as a mild sedative, which can help with the sleep disturbances so common during the menopausal transition.
Women who’ve had a hysterectomy don’t need progesterone; however, women who’ve had a uterine ablation do still need it — since ablation doesn’t destroy every endometrial cell (and cancer risk remains).
No. Treatment with MHT is based on symptoms, not lab values. Hormone levels fluctuate too much to be meaningful guides for dosing, and there’s no “normal” target number to hit.
“What she really wants to feel is better — and that’s what I want for her as well,” Dr. Feitelson said, referring to patients.
No checking of hormone levels is needed before starting, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol or progesterone. No pelvic ultrasound is required either. Annual mammograms and, for women under 65, routine Pap smears should continue as recommended.
MHT is not appropriate for women with a history of stroke, heart attack, blood clot or breast cancer. Women with a history of breast cancer who are experiencing vaginal dryness or discomfort may still be candidates for estrogen applied vaginally, which has minimal systemic absorption — though that conversation should involve an oncologist.
The old rule — lowest dose, shortest time, no more than five years — is no longer the standard. Duration is now individualized.
MHT remains the gold standard — it’s 80% to 90% or more effective at relieving menopausal symptoms. But other options include:
“There have been no studies showing herbal supplements have any effect on menopause symptoms,” Dr. Feitelson said.
Menopause is getting more attention than it has in decades — and for good reason. Women are asking better questions, research has advanced and providers now have both better tools and better data to work with.
“My patients who are finally started on hormone therapy are so grateful that someone listened to them and addressed their concerns,” Dr. Feitelson said. “For so long, particularly for perimenopausal women, someone didn’t listen. Someone told them they were depressed, they were anxious, they were overworked.”
If you’re navigating perimenopause or menopause, the message is clear: The conversation is worth having. And with the new HRT guidelines, providers have much more to offer.